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Abstract
Objective. Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment
with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine
the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone
turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO).
Methods. Patients were randomly stratified according to the duration of pre-study glucocorticoid therapy
[prevention subpopulation (ZOL, n= 144; RIS, n= 144) 43 months, treatment subpopulation (ZOL, n= 272;
RIS, n= 273) >3 months]. Changes in b-C-terminal telopeptides of type 1 collagen (b-CTx), N-terminal
telopeptide of type I collagen (NTx), procollagen type 1 N-terminal propeptide (P1NP) and bone-specific
alkaline phosphatase (BSAP) from baseline were measured on day 10 and months 3, 6 and 12.
Results. At most time points, there were significantly greater reductions (P<0.05) in the concentrations of
serum b-CTx, P1NP and BSAP and urine NTx in subjects on ZOL compared with RIS in both males and
females of the treatment and prevention subpopulations. In pre- and post-menopausal women, there were
significantly greater reductions in the concentrations of BTMs with ZOL compared with RIS. At 12 months,
ZOL had significantly greater reductions compared with RIS (P<0.05) for b-CTx, P1NP, BSAP and NTx
levels, independent of glucocorticoid dose.
Conclusions. Once-yearly i.v. infusion of ZOL 5 mg was well tolerated in different subgroups of GIO
patients. ZOL was non-inferior to RIS and even superior to RIS in the response of BTMs in GIO patients.
Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00100620.
Key words: zoledronic acid, risedronate, glucocorticoids, glucocorticoid-induced osteoporosis, bone turnover
markers.
Introduction
Glucocorticoid-induced osteoporosis (GIO) is the most
common form of secondary osteoporosis, with fractures
occurring in 3050% of patients receiving long-term
glucocorticoid (GC) therapy. Although GCs have favour-
able therapeutic effects in a variety of inflammatory dis-
eases, they cause significant bone loss and increase bone
fragility and associated bone fractures among long-term
users in a GC dose-dependent manner [14]. Men and
post-menopausal women are at greatest risk, and there
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is a particularly high prevalence of symptomatic and
asymptomatic vertebral fractures in post-menopausal
women (37%, with two or more asymptomatic vertebral
fractures reported in 14.5% of patients) on long-term GC
therapy [57].
Although established treatment is available in many
countries, and clinical guidelines recommend bispho-
sphonates for prevention and treatment of GIO, access
to such treatments is not available for many patients, as
the severity of this condition has often been underesti-
mated by the medical community. Many hospitalized pa-
tients who should have received treatments such as
bisphosphonates, HRT or other medications including
vitamin D, calcium and calcitonin to prevent GIO, often
do not receive them. A survey on patients taking oral cor-
ticosteroids has shown that only 8% of hospitalized pa-
tients and 14% of those in general practice were receiving
prophylactic medication to prevent bone loss [8, 9].
Prevention and treatment for GIO is currently best
established for bisphosphonates [10, 11]. In placebo-
controlled trials, bisphosphonates such as risedronate
(RIS) and alendronate have been shown to increase
bone mineral density (BMD) and reduce the risk of verte-
bral fractures in patients initiating corticosteroids or
receiving such treatment for a longer period of time
[1216].
Regulatory approval for the treatment and prevention of
GIO has been granted for bisphosphonates, including the
oral agents RIS and alendronate and i.v. zoledronic acid
(ZOL). In clinical practice, compliance with daily oral
bisphosphonate therapy is reportedly low due to difficul-
ties in adhering to the strict dosing regimen of posture
and fasting [17], which may pose particular issues in
those taking GCs concomitantly with multiple other
medications. In addition, the low bioavailability of oral
bisphosphonates and poor tolerability due to upper
gastrointestinal adverse events are of concern. Up to
50% of patients fail to adhere or comply with a daily
oral treatment regimen within 1 year, which has been
associated with higher fracture rates [18].
Once-yearly i.v. infusion of ZOL increases BMD and re-
duces fracture risk in women with post-menopausal
osteoporosis [19]. It also reduces subsequent fractures
and increases survival rate in patients who have had a
prior low-trauma hip fracture [20]. ZOL is contraindicated
in patients with creatinine clearance <35 ml/min or in pa-
tients with evidence of acute renal impairment. Increasing
the infusion time for ZOL from 5 to 15 min has been shown
to have fewer adverse effects on renal function. Therefore,
a minimum infusion time of 15 min is strongly recom-
mended. The renal safety of ZOL has been shown in
osteoporotic post-menopausal women, provided the infu-
sions lasted at least 15 min [21]. The first infusion of ZOL is
associated with acute flu-like symptoms, but these are
generally mild and transient and disappear with subse-
quent infusions [22]. However, although RIS has been
shown to substantially reduce the occurrence of non-
vertebralnon-hip fractures, taking into consideration the
incidence of vertebral, hip and non-vertebralnon-hip
fractures and their impact on cost and quality of life,
ZOL has been demonstrated to be of great benefit [23].
Furthermore, ZOL 5 mg has been shown to be cost
effective in post-menopausal osteoporosis in Finland,
Norway and the Netherlands [24]. The assessment of re-
sponse to bisphosphonate therapy was reported to be
very useful with bone turnover markers (BTMs) that are
early indicators of bone formation and resorption
[25, 26]. However, there are few studies with the aim of
evaluating changes in BTMs following GC administration
[27]. The authors have previously reported the role of ZOL
in preventing and maintaining BMD in patients on GC ther-
apy [28]. This study reports the effects of a single
once-yearly i.v. infusion of ZOL 5 mg versus daily oral
RIS 5 mg on BTMs in varied subpopulations of patients
with GIO.
Methods
Participants
The study included patients (men and women) between 18
and 85 years of age being treated with at least 7.5 mg oral
prednisone daily (or equivalent systemic GCs) and ex-
pected to continue GCs for at least another 12 months.
Participants were enrolled from 54 centres in 16 countries
of North and South America, Asia, Australia and Europe.
They were selected from two cohorts: those who started
taking GCs within the last 3 months and those who had
been taking GCs for more than 3 months. They were
required to have at least three evaluable vertebrae in the
lumbar spine region (L1L4) to be eligible for inclusion,
determined by lumbar spine radiography screening.
Subjects previously treated with bisphosphonates
(except according to the washout schedule at the time
of randomization: 2 years if used for 548 weeks; 1 year
if used for >8 weeks but <48 weeks; 6 months if used for
>2 weeks but48 weeks; 2 months if used for42 weeks),
sodium fluoride or elemental fluoride (>1500 mg), stron-
tium ranelate, HRT (except low-dose vaginal oestrogen
such as 17b-oestradiol 40.2 mg/day or oestrophitate
41.5 mg/day), calcitonin or calcitriol (>1.5 mg/week)
were excluded. Patients were also excluded if they were
pregnant, had a history of cancer, osteogenesis imper-
fecta, multiple myeloma, Paget’s disease or renal impair-
ment (creatinine clearance <30 ml/min) or a serum
25-hydroxyvitamin D concentration <29 nmol/ml. Written
informed consent was obtained from all subjects before
entering the study. The study was approved by the local
institutional review boards/independent ethics committee/
research ethics boards (for names of the local institutional
review boards/independent ethics committee/research
ethics boards, please see supplementary data, available
at Rheumatology Online). The study was conducted ac-
cording to the ethical principles of the Declaration of
Helsinki. The trial identifier for ClinicalTrials.gov is
NCT00100620.
Study design
This was a post hoc analysis of a multinational, multicen-
tre, 12-month, double-blind, double-dummy, stratified,
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active controlled parallel group study where patients were
randomly selected to receive either once-yearly i.v. infu-
sion of ZOL 5 mg and daily oral placebo capsules or daily
oral RIS 5 mg capsules and a once-yearly i.v. infusion of
placebo [28]. Subjects received 5 mg of ZOL or placebo
as a slow peripheral i.v. infusion of 100 ml over 15 min. RIS
or matching oral placebo capsules were taken daily at
least 30 min before the first food or drink of the day. All
patients received daily supplemental vitamin D at a dose
between 400 and 1200 IU and elemental calcium
1000 mg/day starting up to 28 days (visit 1) before the
infusion and continuing throughout the trial. Patients
were classified according to the duration of their
pre-study GC therapy (prevention subpopulation 43
months, treatment subpopulation >3 months), gender
(male and female) and menopausal status in females (pre-
menopausal and post-menopausal). The study was origin-
ally designed to show non-inferiority of ZOL to RIS for
lumbar spine BMD and the results were published [28].
Markers of bone turnover
BTMs were assessed as secondary endpoints for this trial.
Markers for bone resorption [b-C-terminal telopeptide of
type I collagen (b-CTx), N-terminal telopeptide of type I
collagen (NTx)] and formation [procollagen type I
amino-terminal propeptide (P1NP), bone-specific alkaline
phosphatase (BSAP)] were measured at baseline. The
relative changes of BTMs from baseline at different time
intervals of 10 days and 3, 6 and 12 months were mea-
sured. Specific serum tests were performed for b-CTx,
P1NP and BSAP analysis. Blood was drawn from patients
within 28 days before the first dose of study drug was
administered at baseline and at all subsequent visits
until month 12. In the prevention arm of this study, base-
line samples were drawn after patients received their first
dose of GC. Urinary NTx and creatinine were measured on
second morning-voided urine samples. Serum and urine
samples used to assess BTMs were collected after an
overnight fast of at least 8 hours. Calcium and vitamin D
were not to be taken on the morning prior to a scheduled
blood draw. Patients were instructed to take their oral
study medication as usual.
Serum b-CTx was measured using electrochemilumi-
nescence immunoassay (Elecsys Immunoassay System,
Roche, Basel, Switzerland) [coefficient of variation (CV)
within assay <7%, between assay <10%]; P1NP was
measured using UniQ PINP RIA (Orion Diagnostica Oy,
Espoo, Finland; CV within and between assay <8%) and
BSAP was measured by using immunoradiometric assay
with Tandem-R Ostase (Beckman Coulter, Fullerton, CA,
USA) (CV within assay <8%, between assay <6%).
Urine NTx was measured using ELISA (Osteomark,
Ostex International Inc., Seattle, WA, USA; CV within
assay <12%, between assay <8%). The NTx results
were expressed in nanomoles of bone collagen equivalent
(BCE) per litre and were corrected by creatinine concen-
tration (mM) to be expressed in nanomoles BCE per
millimole. Urine creatinine was measured by the
modified Jaffe method using a modular analyser
(Roche Diagnostics, Mannheim, Germany) [29, 30]. All
these analyses were performed at the Bone and
Cartilage Markers Laboratory at the University of Lie`ge
(Lie`ge, Belgium).
At the end of the study, patients were given a patient
preference questionnaire to determine their preference for
different treatment modalities. Patients were asked which
treatment was more convenient, more satisfying, which
they would be more willing to take for a long period of
time and overall preference. Responses were evaluated
according to subpopulation and treatment.
Statistical analysis
BTMs were analysed in the modified intention-to-treat
group, which consisted of all patients in the intention-to-
treat population who received study drug and who had an
evaluable baseline assessment for the endpoint of inter-
est. The biomarker parameters were analysed based on
the ratio of the post-baseline value relative to baseline
using a loge transformation at each visit, which allows
for an interpretation that is similar to the analysis of per-
centage change from baseline. A three-way analysis of
covariance (ANCOVA) with treatment group, study region
and loge (baseline value) was performed on the log-
transformed ratio (visit/baseline) at each post-baseline
time point (day 10 and months 3, 6 and 12) in each sub-
population. Treatment-by-factor interactions with gender,
menopausal status and GC dose at the corresponding
study time (i.e. GC dose at the time of randomization
and mean GC dose during the study and at the end of
treatment) for biochemical markers of bone turnover were
investigated using a three-way ANCOVA model. To
assess the use of prednisone at randomization, during
the study and at the end of study for the biochemical
markers, the different types of oral GCs were transformed
to a prednisone-equivalent dose. For statistical analyses,
subjects were grouped into low, medium and high dose of
daily prednisone-equivalent GC according to the following
dose categories: <7.5, 7.5 to <12, >12 mg/day, respect-
ively. For statistical comparisons, a P-value of 0.05 was
considered statistically significant.
Results
Of the 833 patients randomly selected, 416 received ZOL
and 417 received RIS (Fig. 1). These groups were further
divided into treatment (ZOL, n= 272; RIS, n= 273) and
prevention subpopulations (ZOL, n= 144; RIS, n= 144).
Overall, 771 subjects (93%) completed the trial.
Baseline characteristics
Baseline characteristics of the subjects were well
balanced between the ZOL and RIS groups (Table 1). Of
the 568 women randomized, 373 were post-menopausal.
In the ZOL group, 5 men and 13 women and in the RIS
group 5 men and 7 women had a history of vertebral frac-
tures at baseline. The commonly reported active medical
conditions at baseline were RA and SLE (Table 1). The
prednisone-equivalent dose of GCs was similar for both
1060 www.rheumatology.oxfordjournals.org
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the ZOL and RIS treatment groups in the treatment and
prevention subpopulations (Table 1). The treatment sub-
population has significantly lower b-CTx and significantly
higher BSAP and P1NP compared with the prevention
subpopulation (P< 0.05). There was no significant differ-
ence between the two subpopulations in the baseline
serum values for NTx (Supplementary Table 1, available
at Rheumatology Online).
Bone resorption markers
The post-baseline analysis showed that the concentra-
tions of BTMs (serum b-CTx and urinary NTx) consistently
decreased from baseline, at all time points, in both male
and female subgroups of ZOL and RIS (Fig. 2A and B).
There were significantly greater reductions (P< 0.05) in
serum b-CTx and urine NTx levels in both male and
female subjects on ZOL therapy compared with those
on RIS therapy in the treatment and prevention subpopu-
lations at day 10 and months 3, 6 and 12, with the excep-
tion of NTx for the male prevention subpopulation at
month 12.
Bone formation markers
There were significantly greater reductions (P< 0.05) in
both serum P1NP and BSAP concentrations with ZOL
treatment compared with RIS treatment for both male
and female subgroups at different post-baseline time
points (Fig. 2C and D). Serum P1NP levels also decreased
more significantly with ZOL therapy compared with RIS at
all post-baseline time points in females of the prevention
subpopulation. For the male and female subgroups of the
treatment subpopulation who were on RIS therapy, P1NP
concentrations did not change much from baseline to day
10; however, they decreased significantly at months 3, 6
and 12. In the prevention subpopulation, BSAP levels
were reduced more significantly with ZOL at months 3
and 6 in females and at month 3 in males (Fig. 2D).
Menopausal status
Analyses of results on the basis of menopausal criteria
demonstrated that there was a significantly greater reduc-
tion in the concentrations of the biomarkers with ZOL
treatment compared with RIS in both pre- and post-
menopausal women (Fig. 3AD).
Prednisone-equivalent dose effect
The influence of prednisone-equivalent dose (<7.5, 7.5 to
<12 and >12 mg/day) on the response of ZOL and RIS to
biochemical markers of bone turnover was analysed at
different time points. Results of the treatment effect at
12 months revealed that ZOL-treated subjects had signifi-
cantly greater reductions in b-CTx, NTx, BSAP and P1NP
compared with RIS-treated subjects (P< 0.05) for both
treatment and prevention subpopulations, which was
FIG. 1 Schematic representation of participant disposition for the study.
b-CTx, NTx, P1NP and BSAP were analysed for both treatment and prevention subpopulations at various time points.
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independent of prednisone-equivalent dose at the end of
the study (Table 2).
Patient preference for treatment regimen
The results on patient preference (based on the responses
to the questionnaire) for treatment regimen are summar-
ized in Table 3. For all four types of questionnaires, a
once-yearly infusion was preferred by the majority of
patients regardless of subpopulation, gender or meno-
pausal status.
Discussion
A single infusion of ZOL has been shown to
provide greater increases and maintenance of BMD and
a more rapid and substantial decrease in BTMs than
TABLE 1 Baseline characteristics of the treatment and prevention subpopulations
Characteristics
Treatment subpopulation Prevention subpopulation
ZOL
(n=272)
RIS
(n=273)
ZOL
(n=144)
RIS
(n=144)
Females, n (%) 185 (68) 183 (67) 100 (69) 100 (69)
Post-menopausal females, n (%) 118 (64) 117 (64) 69 (69) 69 (69)
Males, n (%) 87 (32) 90 (33) 44 (31) 44 (31)
Age (years), mean (S.D.) 53.2 (14) 52.7 (13.7) 56.3 (15.4) 58.1 (14.7)
Age group (years), n (%)
<35 29 (10.7) 30 (11) 15 (10.4) 12 (8.3)
3550 82 (30.1) 89 (32.6) 33 (22.9) 27 (18.8)
5164 96 (35.3) 94 (34.4) 45 (31.3) 50 (34.7)
6574 52 (19.1) 48 (17.6) 35 (24.3) 35 (24.3)
575 13 (4.8) 12 (4.4) 16 (11.1) 20 (13.9)
Serum b-CTx concentration (ng/ml), median (IQR)
Males 0.35 (0.27) 0.37 (0.26) 0.42 (0.26) 0.45 (0.24)
Females 0.32 (0.26) 0.31 (0.27) 0.41 (0.26) 0.39 (0.31)
RAa 0.38 (0.25) 0.35 (0.30) 0.47 (0.32) 0.40 (0.31)
SLEb 0.26 (0.20) 0.25 (0.30) 0.28 (0.34) 0.31 (0.30)
Serum BSAP concentration (ng/ml), median (IQR)
Males 8.16 (4.62) 8.52 (4.34) 7.05 (2.17) 6.80 (3.19)
Females 7.98 (4.44) 8.06 (3.63) 7.79 (4.12) 6.93 (3.66)
RAa 8.75 (4.56) 8.78 (4.0) 8.08 (4.79) 7.39 (5.34)
SLEb 7.43 (3.21) 7.98 (4.34) 7.68 (2.51) 6.93 (4.06)
Serum P1NP concentration (ng/ml), median (IQR)
Males 38.44 (24.42) 33.32 (24.88) 27.07 (18.49) 24.03 (24.30)
Females 38.50 (29.06) 40.34 (27.22) 37.72 (31.16) 30.69 (22.47)
RAa 45.10 (24.48) 45.14 (28.75) 45.49 (24.92) 35.79 (26.86)
SLEb 35.52 (20.43) 36.11 (17.35) 28.81 (40.86) 24.98 (12.87)
Urine NTx concentration (nmol BCE/mmol creatinine), median (IQR)
Males 42.34 (27.84) 43.09 (26.85) 46.67 (43.09) 44.87 (31.98)
Females 38.68 (32.37) 42.19 (32.55) 55.03 (45.51) 48.36 (37.51)
RAa 50.18 (33.19) 45.01 (30.23) 54.19 (48.7) 47.46 (39.02)
SLEb 31.69 (24.41) 34.45 (45.41) 45.47 (59.09) 55.49 (61.51)
Lumbar spine T-score, mean (S.D.) 1.34 (1.34) 1.4 (1.28) 0.95 (1.45) 0.91 (1.44)
Prednisone-equivalent dose (mg/day), n (%)
<7.5 3 (1.1) 3 (1.1) 3 (2.1) -
7.5 to <12 193 (71.0) 204 (74.7) 78 (54.2) 74 (51.4)
512 76 (27.9) 66 (24.2) 63 (43.87) 70 (48.6)
History of most recent vertebral fracture, n (%)
Males 4 (4.6) 3 (3.3) 1 (2.3) 2 (4.5)
Females 8 (4.3) 7 (3.8) 5 (5) 0
Baseline serum 25-OH vitamin D level (nmol/l)
Nichols methodc, mean (S.D.) 62.12 (30.30) 64.29 (36.81) 59.92 (26.40) 54.92 (20.87)
DiaSorin methodc, mean (S.D.) 44.39 (15.80) 44.50 (19.34) 54.20 (19.86) 57.44 (39.13)
IQR: interquartile range. aPatients with active RA. bPatients with active SLE. cPrior to August 2005, the Nichols assay was
used to measure vitamin D except when the value was <29.9 nmol/l, in which case the DiaSorin assay was used. Starting in
August 2005, only the DiaSorin assay was used; a repeat test was allowed. The last value prior to randomization is presented
for each assay, so some values may be below the inclusion limit.
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FIG. 2 Changes in the concentrations (median) of bone resorption and bone formation markers.
Bone resorption markers [serum b-CTx (A) and urine NTx (B)] and bone formation markers [serum P1NP (C) and serum
BSAP (D)], overtime in the male and female subgroups of the treatment and prevention subpopulations. P< 0.05 shows
statistical significance; *P< 0.05 (male subjects), yP< 0.05 (female subjects). Error bars represent 95% CIs.
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FIG. 3 Changes in BTM concentrations (median) over time in the pre- and post-menopausal female subgroups of the
treatment and prevention subpopulations.
(A) b-CTx, (B) NTx, (C) P1NP and (D) BSAP. BTM analyses were done with loge ratios of drug group to baseline with an
ANCOVA model adjusted for drug group, study region and loge of baseline. P-values compare changes in BTMs relative
to baseline between study drugs. P< 0.05 shows statistical significance; *P< 0.05 (pre-menopausal),
y
P< 0.05 (post-
menopausal). Error bars represent 95% CIs.
1064 www.rheumatology.oxfordjournals.org
Jean-Pierre Devogelaer et al.
daily RIS [28]. The present analyses demonstrated that
5 mg of ZOL given once yearly as a single i.v. infusion is
able to exert its effect on BTMs in patients with GIO re-
gardless of gender, menopausal status and independent
of the GC dose received.
Although GIO is generally regarded as a condition with
low bone turnover, especially in patients with chronic GC
use, our baseline markers were generally not that low.
However, markers of resorption such as b-CTx were
higher in the prevention arm versus the treatment arm at
baseline, consistent with results of previous studies [31,
32]. This observation likely reflects that the underlying in-
flammatory disease for which the GCs are being pre-
scribed is driving bone resorption. In contrast, levels of
the bone formation marker serum P1NP were lower at
baseline in the prevention arm, suggesting that the under-
lying inflammatory disease is itself contributing to the
negative balance of bone resorption and formation.
In the present study, once-yearly ZOL 5 mg i.v. infusion
was associated with statistically significant reductions in
BTMs in multiple subgroups of patients with GIO. The
concentrations of bone resorption markers (b-CTx and
NTx) were rapidly reduced at different post-baseline
time points by both treatments (RIS and ZOL), although
the effect was more rapid and more marked for ZOL.
Similar data from a male osteoporosis study recently re-
ported a more pronounced effect of ZOL compared with
oral alendronate in the reduction of BTM concentrations at
different post-baseline time points [33]. In this study, while
there was a decrease in markers of bone formation (P1NP
and BSAP), the effect was delayed. These results indicate
a significant decrease in the elevated bone resorption rate
and only a slightly higher inhibition of the already low bone
formation rate by ZOL [34]. As reported in previous stu-
dies on ZOL [19, 20, 28], the nadir for BTMs is observed at
the time of the earliest assessment at approximately day
TABLE 2 Between-treatment comparison at 12 months for b-CTx, NTx, BSAP and P1NP with glucocorticoid (GC) doses
at the end of treatment by subpopulation
GC dose (mg/day) n (ZOL/RIS)
Relative treatment
effecta
95% CI
of ratio
Within GC
dose P-value
Treatment by
GC dose interaction
P-value
b-CTx (treatment subpopulation)
<7.5 53/41 0.62 0.45, 0.85 0.004* 0.89
7.5 to <12 150/155 0.59 0.49, 0.70 <0.0001*
512 43/44 0.65 0.47, 0.9 0.0105*
b-CTx (prevention subpopulation)
<7.5 40/41 0.65 0.46, 0.92 0.0156* 0.82
7.5 to <12 63/64 0.61 0.49, 0.76 <0.0001*
512 16/18 0.46 0.22, 0.94 0.0336*
NTx (treatment subpopulation)
<7.5 52/42 0.89 0.69, 1.14 0.3374 0.33
7.5 to <12 151/158 0.79 0.70, 0.90 0.0003*
512 44/46 0.71 0.57, 0.88 0.0023*
NTx (prevention subpopulation)
<7.5 39/43 0.80 0.62, 1.03 0.0814 0.95
7.5 to <12 66/63 0.76 0.64, 0.91 0.0037*
512 18/19 0.67 0.48, 0.93 0.0197*
BSAP (treatment subpopulation)
<7.5 55/42 0.96 0.83, 1.10 0.5470 0.20
7.5 to <12 152/160 0.86 0.80, 0.93 0.0001*
512 45/45 0.97 0.85, 1.11 0.6735
BSAP (prevention subpopulation)
<7.5 40/44 0.88 0.75, 1.03 0.1141 0.62
7.5 to <12 66/65 0.92 0.83, 1.03 0.1425
512 18/19 0.99 0.80, 1.22 0.9058
P1NP (treatment subpopulation)
<7.5 55/42 0.88 0.71, 1.09 0.2407 0.28
7.5 to <12 152/159 0.78 0.71, 0.87 <0.0001*
512 45/45 0.91 0.76, 1.10 0.3334
P1NP (prevention subpopulation)
<7.5 40/44 0.90 0.73, 1.11 0.3106 0.31
7.5 to <12 66/65 0.91 0.79, 1.06 0.2419
512 18/18 0.67 0.46, 0.98 0.0386*
aRelative treatment effect: the exponential of the least squares mean (LSM) difference on the loge ratio scale. For values <1,
ZOL has a greater reduction than RIS. *Significant P< 0.05.
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10, regardless of subgroup. These early changes in BTMs
may be useful in assessing response to ZOL therapy in
patients with GIO. The authors have previously published
results of a study that showed that ZOL increased lumbar
spine BMD, measured by dual-energy X-ray absorpti-
ometry, in both prevention and treatment subgroups.
A single once-yearly 5 mg i.v. infusion of ZOL was
non-inferior and possibly more effective than daily 5 mg
oral RIS for the prevention and treatment of bone loss
associated with GC use [28]. BMD measurement alone
is not considered to be sensitive enough to assess bone
strength; however, measurement of biochemical markers
of bone turnover can be a useful tool to assist in the as-
sessment of treatment response in patients with GIO who
are on anti-resorptive therapy. Several earlier studies have
reported that increases in BTM levels correlate with BMD
loss at some skeletal sites and were predictive of fracture
risk [3541]. Anti-resorptive therapies, such as bispho-
sphonates, have been used to reduce the risk of osteo-
porotic vertebral, hip and other non-vertebral fractures, to
maintain or improve bone mass and to suppress exces-
sive bone turnover. However, in this study the number of
subjects with clinical fractures or new morphometric
vertebral fractures in the overall study population was
too small to assess whether the reduction in biochemical
markers of bone turnover correlate to a clinically mean-
ingful reduction in fracture risk. Earlier studies have
demonstrated that a once-yearly 5 mg i.v. infusion of
ZOL is effective in preventing fractures in other osteopor-
otic subpopulations [20, 42, 43]. Hence we speculate that
an annual infusion of 5 mg of ZOL may be efficacious in
preventing fractures in different patient subgroups with
GIO.
As previously published, this study has shown that
ZOL has a good safety and tolerability profile [28]. The
strength of this post hoc analysis is its large population
size, where subjects were stratified into prevention and
treatment subpopulations based on prior GC therapy and
gender, which provided a meaningful basis for analyses
by menopausal status. Hence the present study could
identify the effects of anti-resorptive therapy in sub-
groups of patients with GIO. The study limitation with
respect to BTM is that it was of short duration (12
months) and was not designed to assess BTM endpoints
for the primary efficacy objective. There were insufficient
numbers of clinical vertebral fractures and morphometric
TABLE 3 Patient preferences for treatment regimen [based on ITT population (treatment and prevention
subpopulations)]
Patient
preference
More
convenient,
n (%)
More
satisfying,
n (%)
More willing to
take for a long
period of time,
n (%)
Overall
preference,
n (%)
Treatment
Male (161) Once a year i.v. 133 (82.6) 127 (78.9) 137 (85.1) 134 (83.2)
Once daily pill 12 (7.5) 15 (9.3) 15 (9.3) 15 (9.3)
Both are equal 15 (9.3) 19 (11.8) 9 (5.6) 12 (7.5)
Female (353) Once a year i.v. 286 (81.0) 278 (78.8) 293 (83.0) 299 (84.7)
Once daily pill 32 (9.1) 28 (7.9) 35 (9.9) 37 (10.5)
Both are equal 35 (9.9) 47 (13.3) 25 (7.1) 17 (4.8)
Prevention
Male (80) Once a year i.v. 62 (77.5) 58 (72.5) 66 (82.5) 63 (78.8)
Once daily pill 6 (7.5) 6 (7.5) 8 (10.0) 9 (11.3)
Both are equal 12 (15.0) 16 (20.0) 6 (7.5) 8 (10.0)
Female (189) Once a year i.v. 155 (82.0) 150 (79.4) 163 (86.2) 160 (84.7)
Once daily pill 18 (9.5) 15 (7.9) 15 (7.9) 18 (9.5)
Both are equal 16 (8.5) 24 (12.7) 11 (5.8) 11 (5.8)
Treatment
Post-menopausal (227) Once a year i.v. 177 (78.0) 172 (75.8) 183 (80.6) 187 (82.4)
Once daily pill 24 (10.6) 20 (8.8) 26 (11.5) 28 (12.3)
Both are equal 26 (11.5) 35 (15.4) 18 (7.9) 12 (5.3)
Pre-menopausal (126) Once a year i.v. 109 (86.5) 106 (84.1) 110 (87.3) 112 (88.9)
Once daily pill 8 (6.3) 8 (6.3) 9 (7.1) 9 (7.1)
Both are equal 9 (7.1) 12 (9.5) 7 (5.6) 5 (4.0)
Prevention
Post-menopausal (131) Once a year i.v. 102 (77.9) 101 (77.1) 109 (83.2) 107 (81.7)
Once daily pill 16 (12.2) 12 (9.2) 13 (9.9) 16 (12.2)
Both are equal 13 (9.9) 18 (13.7) 9 (6.9) 8 (6.1)
Pre-menopausal (58) Once a year i.v. 53 (91.4) 49 (84.5) 54 (93.1) 53 (91.4)
Once daily pill 2 (3.4) 3 (5.2) 2 (3.4) 2 (3.4)
Both are equal 3 (5.2) 6 (10.3) 2 (3.4) 3 (5.2)
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vertebral fractures to assess the relationship between
changes in bone markers and fracture risk reduction in
patients with GIO. Patient preference for once-yearly i.v.
infusion of ZOL over oral bisphosphonate was in agree-
ment with previous studies [44, 45]. This may be attrib-
uted to the convenience associated with the once-yearly
frequency of ZOL administration compared with daily
oral RIS, leading to better compliance and hence con-
tributing to better efficacy.
Overall, ZOL was found to be an effective and well-tol-
erated bisphosphonate in the management of patients
with GIO. The rapid and sustained reductions of BTMs
after ZOL administration were replicated across multiple
subgroups of patients with GIO, including men and pre-
and post-menopausal women, and were independent of
GC doses.
Conclusions
In conclusion, a single 5 mg i.v. infusion of ZOL induced a
significant and sustained reduction in biochemical mar-
kers of bone turnover, regardless of baseline characteris-
tics such as gender, menopausal status and prednisone-
equivalent GC dose. A rapid decrease in b-CTx was
observed within days of ZOL administration, followed by
a slow increase over the course of the year, suggesting
that in patients on high-dose GC and with underlying in-
flammatory processes, bone turnover remains active des-
pite potent anti-resorptive therapy. Further studies to
assess the impact of BTM reduction on osteoporotic frac-
tures in different subgroups of patients with GIO are
warranted.
Rheumatology key messages
. Patients with glucocorticoid-induced osteoporosis
undergo rapid bone loss early after treatment
initiation.
. Treatment with bisphosphonates rapidly decreases
the bone resorption marker b-CTx in patients with
glucocorticoid-induced osteoporosis.
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